Vaccination of the global population against COVID-19 is a great scientific, logistical, and
moral challenge. Despite the rapid development and authorization of several full-length …

Virus-like particles (VLPs) are viral structural protein that are noninfectious as they do not
contain viral genetic materials. They are safe and effective immune stimulators and play …

Rapid emergence of the SARS-CoV-2 variants has dampened the protective efficacy of
existing authorized vaccines. Nanoparticle platforms offer a means to improve vaccine …

SARS-CoV-2 protein subunit vaccines are currently being evaluated by multiple
manufacturers to address the global vaccine equity gap, and need for low-cost, easy to …

Proteins can be empowered via SpyTag for anchoring and nanoassembly, through covalent
bonding to SpyCatcher partners. Here we generate a switchable version of SpyCatcher …

Highlights•Studying VLPs gives important insights into how the immune system makes
decisions.•Spacing antigens using DNA indicates the optimal separation for B cell …

Saturation suppressor mutagenesis was used to generate thermostable mutants of the
SARS-CoV-2 spike receptor-binding domain (RBD). A triple mutant with an increase in …

Adenovirus vector vaccines have been widely and successfully deployed in response to
coronavirus disease 2019 (COVID-19). However, despite inducing potent T cell immunity …

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the
associated coronavirus disease 2019 (COVID-19), which severely affect the respiratory …

SARS-CoV-2 is evolving with increased transmission, host range, pathogenicity, and
virulence. The original and mutant viruses escape host innate (Interferon) immunity and …